Myriad Genetics (MYGN) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Myriad Genetics (MYGN) overview

Myriad Genetics (MYGN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 825m and operating profit of USD -387m; the year-end share price was 6.15 USD and market capitalisation was USD 575m. Myriad Genetics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Myriad Genetics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 368mFY 2025
Share price6.15 USDFY 2025 year end
RevenueUSD 825mFY 2025
Operating profitUSD -387mFY 2025
Net earningsUSD -366mFY 2025
Market capitalisationUSD 575mFY 2025 year end

About Myriad Genetics

Myriad Genetics develops and commercializes molecular diagnostic tests that provide genetic insights to patients and healthcare providers. Its tests assess disease risk and progression and help guide treatment decisions across specialties, including cancer, prenatal health, and mental health. The company also provides biopharma services such as biomarker identification, companion diagnostic development, regulatory registration, and commercialization.

Generate the Myriad Genetics report

Myriad Genetics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Myriad Genetics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Myriad Genetics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.